Advertisement

Non-steroidal anti-inflammatory drugs

  • Ali J. Olyaei
  • Andrew Whelton
  • Til Sturmer
  • George A. Porter

The discovery and commercialization of asprin over 100 years ago, and the introduction of other non-steroidal anti-inflammatory drugs (NSAIDs) have had a profound impact on the practice of medicine and the treatment of the inflammatory conditions. Widespread access and over-the-counter availability of these agents has lead to the impression that these drugs are safe and relatively void of toxicity. NSAID use can pose substantial risks to patients, especially when used chronically. Gastrointestinal (GI) complications associated with NSAID use are the most common serious adverse drug reaction reported in the United States. Additionally, aspirin is extensively used as an anti-platelet agent, as well as an analgesic agent. Aspirin, as well as other non-specific NSAID’s have a demonstrated risk of gastrointestinal hemorrhage.

Keywords

Nephrotic Syndrome Angiotensin Converting Enzyme Inhibitor Interstitial Nephritis Acute Interstitial Nephritis Nonselective NSAID 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bennett WM, Henrich WL, Stoff JS, Bennett WM, Henrich WL, Stoff JS. The renal effects of nonsteroidal anti-inflammatory drugs: summary and recommendations. American Journal of Kidney Diseases 1996;28: S56-S62.PubMedGoogle Scholar
  2. 2.
    Bennett WM, Porter GA, Bennett WM, Porter GA. Analgesic nephropathy and the use of nonsteroidal anti-inflammatory drugs in renal patients: new insight. Journal of Nephrology 1998;11: 70-75.PubMedGoogle Scholar
  3. 3.
    Whelton A, Hamilton CW, Whelton A, Hamilton CW. Nonsteroidal anti-inflammatory drugs: effects on kidney function. Journal of Clinical Pharmacology 1991;31: 588-598.3A. Source: IMS Health, IMS National Prescription Audit PLUS (TM), 3/2007, used with permissionGoogle Scholar
  4. 4.
    Whelton A, Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. American Journal of Medicine 1999;106: 13S-24S.PubMedGoogle Scholar
  5. 5.
    Brater DC, Brater DC. Anti-inflammatory agents and renal function. Seminars in Arthritis & Rheumatism 2002;32: 33-42.Google Scholar
  6. 6.
    Breyer MD, Hao C, Qi Z, Breyer MD, Hao C, Qi Z. Cyclooxygenase-2 selective inhibitors and the kidney. Current Opinion in Critical Care 2001;7: 393-400.PubMedGoogle Scholar
  7. 7.
    Oates JA, FitzGerald GA, Branch RA et al. Clinical implications of prostaglandin and thromboxane A2 formation (2). New England Journal of Medicine 1988;319: 761-767.PubMedGoogle Scholar
  8. 8.
    FitzGerald GA, Patrono C, FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. New England Journal of Medicine 2001;345: 433-442.PubMedGoogle Scholar
  9. 9.
    Clive DM, Stoff JS, Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal antiinflammatory drugs. New England Journal of Medicine 1984;310: 563-572.PubMedGoogle Scholar
  10. 10.
    Stokes JB, Stokes JB. Effect of prostaglandin E2 on chloride transport across the rabbit thick ascending limb of Henle. Selective inhibitions of the medullary portion. Journal of Clinical Investigation 1979;64: 495-502.PubMedGoogle Scholar
  11. 11.
    Breyer MD, Zhang Y, Guan YF et al. Regulation of renal function by prostaglandin E receptors. Kidney International - Supplement 1998;67: S88-S94.PubMedGoogle Scholar
  12. 12.
    O’Banion MK, Winn VD, Young DA, O’Banion MK, Winn VD, Young DA. cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. Proceedings of the National Academy of Sciences of the United States of America 1992;89: 4888-4892.PubMedGoogle Scholar
  13. 13.
    Crofford LJ, Crofford LJ. COX-1 and COX-2 tissue expression: implications and predictions. Journal of Rheumatology - Supplement 1997;49: 15-19.Google Scholar
  14. 14.
    Hla T, Neilson K, Hla T, Neilson K. Human cyclooxygenase-2 cDNA. Proceedings of the National Academy of Sciences of the United States of America 1992;89: 7384-7388.PubMedGoogle Scholar
  15. 15.
    Komhoff M, Grone HJ, Klein T et al. Localization of cyclooxygenase-1 and -2 in adult and fetal human kidney: implication for renal function. American Journal of Physiology 1997;272: F460-F468.PubMedGoogle Scholar
  16. 16.
    Harris RC, McKanna JA, Akai Y et al. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. Journal of Clinical Investigation 1994;94: 2504-2510.PubMedGoogle Scholar
  17. 17.
    Whelton A, Whelton A. Renal aspects of treatment with conventional nonsteroidal anti-inflammatory drugs versus cyclooxyge-nase-2-specific inhibitors. American Journal of Medicine 2001;110 Suppl 3A: 33S-42S.PubMedGoogle Scholar
  18. 18.
    Blume C, Heise G, Muhlfeld A et al. Effect of flosulide, a selective cyclooxygenase 2 inhibitor, on passive heymann nephritis in the rat. Kidney International 1999;56: 1770-1778.PubMedGoogle Scholar
  19. 19.
    Whelton A, Schulman G, Wallemark C et al. Effects of celecoxib and naproxen on renal function in the elderly. Archives of Internal Medicine 2000;160: 1465-1470.PubMedGoogle Scholar
  20. 20.
    Mitchell JA, Akarasereenont P, Thiemermann C et al. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proceedings of the National Academy of Sciences of the United States of America 1993;90: 11693-11697.PubMedGoogle Scholar
  21. 21.
    McMurray RW, Hardy KJ, McMurray RW, Hardy KJ. Cox-2 inhibitors: today and tomorrow. American Journal of the Medical Sciences 2002;323: 181-189.PubMedGoogle Scholar
  22. 22.
    Harris RC, Harris RC. Cyclooxygenase-2 in the kidney. Journal of the American Society of Nephrology 2000;11: 2387-2394.PubMedGoogle Scholar
  23. 23.
    Stokes JB, Kokko JP, Stokes JB, Kokko JP. Inhibition of sodium transport by prostaglandin E2 across the isolated, perfused rabbit collecting tubule. Journal of Clinical Investigation 1977;59: 1099-1104.PubMedGoogle Scholar
  24. 24.
    Schlondorff D, Schlondorff D. Renal complications of nonsteroidal anti-inflammatory drugs. Kidney International 1993;44: 643-653.PubMedGoogle Scholar
  25. 25.
    Murray MD, Brater DC, Tierney WM et al. Ibuprofen-associated renal impairment in a large general internal medicine practice. American Journal of the Medical Sciences 1990;299: 222-229.PubMedGoogle Scholar
  26. 26.
    Catella-Lawson F, McAdam B, Morrison BW et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. Journal of Pharmacology & Experimental Therapeutics 1999;289: 735-741.Google Scholar
  27. 27.
    Van HA, Schwartz JI, Depre M et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. Journal of Clinical Pharmacology 2000;40: 1109-1120.Google Scholar
  28. 28.
    Ormrod D, Wellington K, Wagstaff AJ, Ormrod D, Wellington K, Wagstaff AJ. Valdecoxib. . Drugs 2002;62: 2059-2071.PubMedGoogle Scholar
  29. 29.
    Sedor JR, Williams SL, Chremos AN et al. Effects of sulindac and indomethacin on renal prostaglandin synthesis. Clinical Pharmacology & Therapeutics 1984;36: 85-91.Google Scholar
  30. 30.
    Berg KJ, Berg KJ. Acute effects of acetylsalicylic acid on renal function in normal man. European Journal of Clinical Pharmacology 1977;11: 117-123.PubMedGoogle Scholar
  31. 31.
    Donker AJ, Arisz L, Brentjens JR et al. The effect of indomethacin on kidney function and plasma renin activity in man. Nephron 1976;17: 288-296.PubMedGoogle Scholar
  32. 32.
    Perez GS, Garcia Rodriguez LA, Raiford DS et al. Nonsteroidal anti-inflammatory drugs and the risk of hospitalization for acute renal failure.. Archives of Internal Medicine 1996;156: 2433-2439.Google Scholar
  33. 32A.
    Schneider V, Levesque LE, Zhang B, Hutchinson T, Brophy JM. Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: A population-based, nested case-control analysis. Am J Epidemiol 2006;164:881-889.PubMedGoogle Scholar
  34. 32B.
    Clinard F, Sgro C, Bardou M, Hillon P, Dumas M, Kreft-Jais C, Escousse A, Bonithon-Kopp C. Association between concomitant use of several systemic NSAIDs and an excess risk of adverse drug reaction. A case/non-case study from the French pharmacovigilance system database. Eur J Clin Pharamcol. 2004;60:279-283Google Scholar
  35. 33.
    Evans JM, McGregor E, McMahon AD et al. Non-steroidal anti-inflammatory drugs and hospitalization for acute renal failure. Qjm 1995;88: 551-557.PubMedGoogle Scholar
  36. 34.
    Griffin MR, Yared A, Ray WA, Griffin MR, Yared A, Ray WA. Nonsteroidal antiinflammatory drugs and acute renal failure in elderly persons. American Journal of Epidemiology 2000;151: 488-496.PubMedGoogle Scholar
  37. 34A.
    Huerta C, Castellsague J, Varas-Lorenzo C, Gracia-Rodriguez LA. Nonsteroidal anti-inflammatory drugs and the risk of ARF in the general population. Am J Kid Dis 2005;45:;531-542PubMedGoogle Scholar
  38. 35.
    Blackshear JL, Napier JS, Davidman M et al. Renal complications of nonsteroidal antiinflammatory drugs: identification and monitoring of those at risk. Seminars in Arthritis & Rheumatism 1985;14: 163-175.Google Scholar
  39. 36.
    Feldman HI, Kinman JL, Berlin JA et al. Parenteral ketorolac: the risk for acute renal failure.. Annals of Internal Medicine 1997;126: 193-199.PubMedGoogle Scholar
  40. 37.
    Zipser RD, Hoefs JC, Speckart PF et al. Prostaglandins: modulators of renal function and pressor resistance in chronic liver disease. Journal of Clinical Endocrinology & Metabolism 1979;48: 895-900.Google Scholar
  41. 38.
    Zipser RD, Radvan GH, Kronborg IJ et al. Urinary thromboxane B2 and prostaglandin E2 in the hepatorenal syndrome: evidence for increased vasoconstrictor and decreased vasodilator factors. Gastroenterology 1983;84: 697-703.PubMedGoogle Scholar
  42. 39.
    Walshe JJ, Venuto RC, Walshe JJ, Venuto RC. Acute oliguric renal failure induced by indomethacin: possible mechanism. Annals of Internal Medicine 1979;91: 47-49.PubMedGoogle Scholar
  43. 40.
    Arisz L, Donker AJ, Brentjens JR et al. The effect of indomethacin on proteinuria and kidney function in the nephrotic syndrome. Acta Medica Scandinavica 1976;199: 121-125.PubMedGoogle Scholar
  44. 41.
    Kleinknecht C, Broyer M, Gubler MC et al. Irreversible renal failure after indomethacin in steroid-resistant nephrosis. New England Journal of Medicine 1980;302: 691.PubMedGoogle Scholar
  45. 42.
    Kimberly RP, Gill JR, Jr., Bowden RE et al. Elevated urinary prostaglandins and the effects of aspirin on renal function in lupus erythematosus. Annals of Internal Medicine 1978;89: 336-341.PubMedGoogle Scholar
  46. 43.
    Fong HJ, Cohen AH, Fong HJ, Cohen AH. Ibuprofen-induced acute renal failure with acute tubular necrosis. American Journal of Nephrology 1982;2: 28-31.PubMedGoogle Scholar
  47. 44.
    Favre L, Glasson P, Vallotton MB, Favre L, Glasson P, Vallotton MB. Reversible acute renal failure from combined triamterene and indomethacin: a study in healthy subjects. Annals of Internal Medicine 1982;96: 317-320.PubMedGoogle Scholar
  48. 45.
    Whelton A, Stout RL, Spilman PS et al. Renal effects of ibuprofen, piroxicam, and sulindac in patients with asymptomatic renal failure. A prospective, randomized, crossover comparison.. Annals of Internal Medicine 1990;112: 568-576.PubMedGoogle Scholar
  49. 46.
    Whelton A, Whelton A. Renal effects of over-the-counter analgesics. Journal of Clinical Pharmacology 1995;35: 454-463.PubMedGoogle Scholar
  50. 47.
    Perazella MA, Perazella MA. Drug-induced hyperkalemia: old culprits and new offenders. American Journal of Medicine 2000;109: 307-314.PubMedGoogle Scholar
  51. 48.
    Galler M, Folkert VW, Schlondorff D, Galler M, Folkert VW, Schlondorff D. Reversible acute renal insufficiency and hyperkalemia following indomethacin therapy. JAMA 1981;246: 154-155.PubMedGoogle Scholar
  52. 49.
    Findling JW, Beckstrom D, Rawsthorne L et al. Indomethacin-induced hyperkalemia in three patients with gouty arthritis. JAMA 1980;244: 1127-1128.PubMedGoogle Scholar
  53. 50.
    Nicholls MG, Espiner EA, Nicholls MG, Espiner EA. Indomethacin-induced azotaemia and hyperkalaemia: a case study. New Zealand Medical Journal 1981;94: 377-379.PubMedGoogle Scholar
  54. 51.
    Paladini G, Tonazzi C, Paladini G, Tonazzi C. Indomethacin-induced hyperkalemia and renal failure in multiple myeloma. Acta Haematologica 1982;68: 256-260.PubMedGoogle Scholar
  55. 52.
    Akbarpour F, Afrasiabi A, Vaziri ND, Akbarpour F, Afrasiabi A, Vaziri ND. Severe hyperkalemia caused by indomethacin and potassium supplementation. Southern Medical Journal 1985;78: 756-757.PubMedGoogle Scholar
  56. 53.
    Mor R, Pitlik S, Rosenfeld JB, Mor R, Pitlik S, Rosenfeld JB. Indomethacin- and Moduretic--induced hyperkalemia. Israel Journal of Medical Sciences 1983;19: 535-537.PubMedGoogle Scholar
  57. 54.
    Goldszer RC, Coodley EL, Rosner MJ et al. Hyperkalemia associated with indomethacin. Archives of Internal Medicine 1981;141: 802-804.PubMedGoogle Scholar
  58. 55.
    MacCarthy EP, Frost GW, Strokes GS, MacCarthy EP, Frost GW, Strokes GS. Indomethacin-induced hyperkalaemia. Medical Journal of Australia 1979;1: 550.PubMedGoogle Scholar
  59. 56.
    Tan SY, Shapiro R, Franco R et al. Indomethacin-induced prostaglandin inhibition with hyperkalemia. A reversible cause of hyporeninemic hypoaldosteronism. Annals of Internal Medicine 1979;90: 783-785.PubMedGoogle Scholar
  60. 57.
    Whelton A, Maurath CJ, Verburg KM et al. Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor. American Journal of Therapeutics 2000;7: 159-175.PubMedGoogle Scholar
  61. 58.
    Palmer RH, Haig AE, Flavin SK, Lyengaer NK. Effects of Ibuprofen, nabumetone and celecoxib on blood pressure control in hypertensive patients on ACE inhibitors. American Journal of Hypertension 2001;14: 85A.Google Scholar
  62. 59.
    White WB, Kent J, Taylor A et al. Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors. Hypertension 2002;39: 929-934.PubMedGoogle Scholar
  63. 60.
    Orloff J, Handler Js, Bergstrom S, Orloff J, Handler Js, Bergstrom S. Effect Of prostaglandin (PGE-1) on the permeability response of toad bladder to vasopressin, theophylline and adenosine 3’, 5’-monophosphate. Nature 1965;205: 397-398.PubMedGoogle Scholar
  64. 61.
    Anderson RJ, Berl T, McDonald KD et al. Evidence for an in vivo antagonism between vasopressin and prostaglandin in the mammalian kidney. Journal of Clinical Investigation 1975;56: 420-426.PubMedGoogle Scholar
  65. 62.
    Schooley RT, Wagley PF, Lietman PS, Schooley RT, Wagley PF, Lietman PS. Edema associated with ibuprofen therapy. JAMA 1977;237: 1716-1717.PubMedGoogle Scholar
  66. 63.
    Blum M, Aviram A, Blum M, Aviram A. Ibuprofen induced hyponatraemia. Rheumatology & Rehabilitation 1980;19: 258-259.Google Scholar
  67. 64.
    Gurwitz JH, Avorn J, Bohn RL et al. Initiation of antihypertensive treatment during nonsteroidal anti-inflammatory drug therapy. JAMA 1994;272: 781-786.PubMedGoogle Scholar
  68. 65.
    Pope JE, Anderson JJ, Felson DT, Pope JE, Anderson JJ, Felson DT. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Archives of Internal Medicine 1993;153: 477-484.PubMedGoogle Scholar
  69. 66.
    Johnson AG, Nguyen TV, Day RO, Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis.. Annals of Internal Medicine 1994;121: 289-300.Google Scholar
  70. 66A.
    Aw TJ, Haas SJ, Liew D, Krum H. Meta-analysis of Cyclooxygenase -2 inhibitors and their effects on blood pressure. Arch Intern Med 2005; 165:490-496PubMedGoogle Scholar
  71. 66B.
    Gaziano JM. Nonnarcotic analgesics and hypertension. Am J Cardiol 2006; 97(suppl):10E-16E.Google Scholar
  72. 67.
    Fogari R, Zoppi A, Carretta R et al. Effect of indomethacin on the antihypertensive efficacy of valsartan and lisinopril: a multicentre study. Journal of Hypertension 2002;20: 1007-1014.PubMedGoogle Scholar
  73. 68.
    Ruoff GE, Ruoff GE. The impact of nonsteroidal anti-inflammatory drugs on hypertension: alternative analgesics for patients at risk. Clinical Therapeutics 1998;20: 376-387.PubMedGoogle Scholar
  74. 69.
    Celis H, Thijs L, Staessen JA et al. Interaction between nonsteroidal anti-inflammatory drug intake and calcium-channel blockerbased antihypertensive treatment in the Syst-Eur trial. Journal of Human Hypertension 2001;15: 613-618.PubMedGoogle Scholar
  75. 69A.
    Wang J, Mullins CD, Mamdani M, Rublee DA, Shaya FT. New diagnosis of hypertension among celecoxib and nonselective NSAID users: A population-based cohort study. Ann Pharmacother 2007;41:937-43.PubMedGoogle Scholar
  76. 70.
    Raij L, Baylis C, Raij L, Baylis C. Glomerular actions of nitric oxide. Kidney International 1995;48: 20-32.PubMedGoogle Scholar
  77. 71.
    Taddei S, Virdis A, Mattei P et al. Aging and endothelial function in normotensive subjects and patients with essential hypertension. Circulation 1995;91: 1981-1987.PubMedGoogle Scholar
  78. 72.
    Forte P, Copland M, Smith LM et al. Basal nitric oxide synthesis in essential hypertension.. Lancet 1997;349: 837-842.PubMedGoogle Scholar
  79. 73.
    Campese VM, Amar M, Anjali C et al. Effect of L-arginine on systemic and renal haemodynamics in salt-sensitive patients with essential hypertension. Journal of Human Hypertension 1997;11: 527-532.PubMedGoogle Scholar
  80. 74.
    Perinotto P, Biggi A, Carra N et al. Angiotensin II and prostaglandin interactions on systemic and renal effects of L-NAME in humans. Journal of the American Society of Nephrology 2001;12: 1706-1712.PubMedGoogle Scholar
  81. 75.
    Mulkerrin EC, Clark BA, Epstein FH, Mulkerrin EC, Clark BA, Epstein FH. Increased salt retention and hypertension from non-steroidal agents in the elderly. Qjm 1997;90: 411-415.PubMedGoogle Scholar
  82. 76.
    Alam S, Purdie DM, Johnson AG, Alam S, Purdie DM, Johnson AG. Evaluation of the potential interaction between NaCl and prostaglandin inhibition in elderly individuals with isolated systolic hypertension. Journal of Hypertension 1999;17: 1195-1202.PubMedGoogle Scholar
  83. 77.
    Brater DC, Anderson S, Baird B et al. Effects of ibuprofen, naproxen, and sulindac on prostaglandins in men. Kidney International 1985;27: 66-73.PubMedGoogle Scholar
  84. 78.
    Bunning RD, Barth WF, Bunning RD, Barth WF. Sulindac. A potentially renal-sparing nonsteroidal anti-inflammatory drug. JAMA 1982;248: 2864-2867.PubMedGoogle Scholar
  85. 79.
    Ciabattoni G, Cinotti GA, Pierucci A et al. Effects of sulindac and ibuprofen in patients with chronic glomerular disease. Evidence for the dependence of renal function on prostacyclin. New England Journal of Medicine 1984;310: 279-283.PubMedGoogle Scholar
  86. 80.
    Klassen DK, Stout RL, Spilman PS et al. Sulindac kinetics and effects on renal function and prostaglandin excretion in renal insufficiency. Journal of Clinical Pharmacology 1989;29: 1037-1042.PubMedGoogle Scholar
  87. 81.
    Mistry CD, Lote CJ, Currie WJ et al. Effects of sulindac on renal function and prostaglandin synthesis in patients with moderate chronic renal insufficiency. Clinical Science 1986;70: 501-505.PubMedGoogle Scholar
  88. 82.
    Quintero E, Gines P, Arroyo V et al. Sulindac reduces the urinary excretion of prostaglandins and impairs renal function in cirrhosis with ascites. Nephron 1986;42: 298-303.PubMedGoogle Scholar
  89. 83.
    Rossert J, Rossert J. Drug-induced acute interstitial nephritis. Kidney International 2001;60: 804-817.PubMedGoogle Scholar
  90. 84.
    Porile JL, Bakris GL, Garella S, Porile JL, Bakris GL, Garella S. Acute interstitial nephritis with glomerulopathy due to nonsteroidal anti-inflammatory agents: a review of its clinical spectrum and effects of steroid therapy. Journal of Clinical Pharmacology 1990;30: 468-475.PubMedGoogle Scholar
  91. 85.
    Rocha JL, Fernandez-Alonso J, Rocha JL, Fernandez-Alonso J. Acute tubulointerstitial nephritis associated with the selective COX-2 enzyme inhibitor, rofecoxib.. Lancet 2001;357: 1946-1947.PubMedGoogle Scholar
  92. 86.
    Henao J, Hisamuddin I, Nzerue CM et al. Celecoxib-induced acute interstitial nephritis.. American Journal of Kidney Diseases 2002;39: 1313-1317.PubMedGoogle Scholar
  93. 87.
    Alper AB, Jr., Meleg-Smith S, Krane NK, Alper ABJ, Meleg-Smith S, Krane NK. Nephrotic syndrome and interstitial nephritis associated with celecoxib. American Journal of Kidney Diseases 2002;40: 1086-1090.PubMedGoogle Scholar
  94. 88.
    Abraham PA, Keane WF, Abraham PA, Keane WF. Glomerular and interstitial disease induced by nonsteroidal anti-inflammatory drugs. American Journal of Nephrology 1984;4: 1-6.PubMedGoogle Scholar
  95. 89.
    Levin ML, Levin ML. Patterns of tubulo-interstitial damage associated with nonsteroidal antiinflammatory drugs. Seminars in Nephrology 1988;8: 55-61.PubMedGoogle Scholar
  96. 90.
    Schwarz A, Krause PH, Kunzendorf U et al. The outcome of acute interstitial nephritis: risk factors for the transition from acute to chronic interstitial nephritis.. Clinical Nephrology 2000;54: 179-190.PubMedGoogle Scholar
  97. 91.
    Ravnskov U, Ravnskov U. Glomerular, tubular and interstitial nephritis associated with non-steroidal antiinflammatory drugs. Evidence of a common mechanism. British Journal of Clinical Pharmacology 1999;47: 203-210.PubMedGoogle Scholar
  98. 92.
    Bender WL, Whelton A, Beschorner WE et al. Interstitial nephritis, proteinuria, and renal failure caused by nonsteroidal anti-inflammatory drugs. Immunologic characterization of the inflammatory infiltrate. American Journal of Medicine 1984;76: 1006-1012.PubMedGoogle Scholar
  99. 93.
    Stachura I, Jayakumar S, Bourke E, Stachura I, Jayakumar S, Bourke E. T and B lymphocyte subsets in fenoprofen nephropathy. American Journal of Medicine 1983;75: 9-16.PubMedGoogle Scholar
  100. 94.
    Shibasaki T, Ishimoto F, Sakai O et al. Clinical characterization of drug-induced allergic nephritis. American Journal of Nephrology 1991;11: 174-180.PubMedGoogle Scholar
  101. 95.
    Radford MG, Jr., Holley KE, Grande JP et al. Reversible membranous nephropathy associated with the use of nonsteroidal antiinflammatory drugs. JAMA 1996;276: 466-469.PubMedGoogle Scholar
  102. 96.
    Perneger TV, Whelton PK, Klag MJ, Perneger TV, Whelton PK, Klag MJ. Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal antiinflammatory drugs. New England Journal of Medicine 1994;331: 1675-1679.PubMedGoogle Scholar
  103. 97.
    Sandler DP, Burr FR, Weinberg CR, Sandler DP, Burr FR, Weinberg CR. Nonsteroidal anti-inflammatory drugs and the risk for chronic renal disease.. Annals of Internal Medicine 1991;115: 165-172.PubMedGoogle Scholar
  104. 98.
    Field TS, Gurwitz JH, Glynn RJ et al. The renal effects of nonsteroidal anti-inflammatory drugs in older people: findings from the Established Populations for Epidemiologic Studies of the Elderly. Journal of the American Geriatrics Society 1999;47: 507-511.PubMedGoogle Scholar
  105. 99.
    Sturmer T, Elseviers MM, De Broe ME, Sturmer T, Elseviers MM, De Broe ME. Nonsteroidal anti-inflammatory drugs and the kidney. . Current Opinion in Nephrology & Hypertension 2001;10: 161-163.Google Scholar
  106. 99A.
    Rexrode KM, Buring JE, Glynn RJ, Stampfer MJ, Youngman LD, Gaziano JM. Analgesic use and renal function in men. JAMA 2001;286:315-321.PubMedGoogle Scholar
  107. 99B.
    Kurth T, Glynn RJ, Walker AM, Rexrode KM, Buring JE, Stampfer MJ, Hennekens CH, Gaziano JM. Analgesic use and change in kidney function in apparently healthy men. Am J Kid Dis 2003;42:234-244.PubMedGoogle Scholar
  108. 99C.
    Curhan GC, Knight EL, Rosner B, Hankinson SE, Stampfer MJ. Lifetime nonnarcotic analgesic use and decline in renal function in women.Arch Intern Med 2004;164:1519-1524PubMedGoogle Scholar
  109. 99D.
    Ibanez, L, Morlans M, Vidal X, Martinez MJ, Laporte JR. Case-control study of regular analgesic and nonsteroidal anti-inflammatoryuse and end-stage renal disease. Kid Internal 2005;67:2393-2398.Google Scholar
  110. 100.
    Sturmer T, Erb A, Keller F et al. Determinants of impaired renal function with use of nonsteroidal anti-inflammatory drugs: the importance of half-life and other medications. American Journal of Medicine 2001;111: 521-527.PubMedGoogle Scholar
  111. 101.
    Calvo-Alen J, De Cos MA, Rodriguez-Valverde V et al. Subclinical renal toxicity in rheumatic patients receiving longterm treatment with nonsteroidal antiinflammatory drugs. Journal of Rheumatology 1994;21: 1742-1747.PubMedGoogle Scholar
  112. 102.
    Segasothy M, Chin GL, Sia KK et al. Chronic nephrotoxicity of anti-inflammatory drugs used in the treatment of arthritis. British Journal of Rheumatology 1995;34: 162-165.PubMedGoogle Scholar
  113. 103.
    Shah GM, Muhalwas KK, Winer RL, Shah GM, Muhalwas KK, Winer RL. Renal papillary necrosis due to ibuprofen. Arthritis & Rheumatism 1981;24: 1208-1210.Google Scholar
  114. 104.
    Robertson CE, Ford MJ, Van S, V et al. Mefenamic acid nephropathy. Lancet 1980;2: 232-233.PubMedGoogle Scholar
  115. 105.
    Husserl FE, Lange RK, Kantrow CM, Jr., Husserl FE, Lange RK, Kantrow CMJ. Renal papillary necrosis and pyelonephritis accompanying fenoprofen therapy. JAMA 1979;242: 1896-1898.PubMedGoogle Scholar
  116. 106.
    Kincaid-Smith P, Kincaid-Smith P. Effects of non-narcotic analgesics on the kidney. Drugs 1986;32 Suppl 4: 109-128.PubMedGoogle Scholar
  117. 107.
    Kirschenbaum MA, White N, Stein JH et al. Redistribution of renal cortical blood flow during inhibition of prostaglandin synthesis. American Journal of Physiology 1974;227: 801-805.PubMedGoogle Scholar
  118. 108.
    Stein JH, Fadem SZ, Stein JH, Fadem SZ. The renal circulation. JAMA 1978;239: 1308-1312.PubMedGoogle Scholar
  119. 109.
    Lourie SH, Denman SJ, Schroeder ET, Lourie SH, Denman SJ, Schroeder ET. Association of renal papillary necrosis and ankylosing spondylitis. Arthritis & Rheumatism 1977;20: 917-921.Google Scholar
  120. 110.
    Morales A, Steyn J, Morales A, Steyn J. Papillary necrosis following phenylbutazone ingestion. Archives of Surgery 1971;103: 420-421.PubMedGoogle Scholar
  121. 111.
    Fored CM, Ejerblad E, Lindblad P et al. Acetaminophen, aspirin, and chronic renal failure.. New England Journal of Medicine 2001;345: 1801-1808.PubMedGoogle Scholar
  122. 112.
    Weisman J, Bloom B. Anuria folloing phenylbutazone therapy. NEJM 1955;252: 1086-1087.PubMedGoogle Scholar
  123. 113.
    Lipsett M, Goldman R. Phenylbutazone toxicity:report of a case of acute renal failure. Annual of Internal Medicine 2007;41: 10751079.Google Scholar
  124. 114.
    Hart D, Ward M, Lifschitz MD, Hart D, Ward M, Lifschitz MD. Suprofen-related nephrotoxicity. A distinct clinical syndrome. Annals of Internal Medicine 1987;106: 235-238.PubMedGoogle Scholar
  125. 115.
    Vane JR, Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature - New Biology 1971;231: 232-235.PubMedGoogle Scholar
  126. 116.
    Verburg KM, Maziasz TJ, Weiner E et al. Cox-2-specific inhibitors: definition of a new therapeutic concept. American Journal of Therapeutics 2001;8: 49-64.PubMedGoogle Scholar
  127. 117.
    Lipsky LP, Abramson SB, Crofford L et al. The classification of cyclooxygenase inhibitors. Journal of Rheumatology 1998;25: 22982303.Google Scholar
  128. 118.
    Silverstein FE, Faich G, Goldstein JL et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.. JAMA 2000;284: 1247-1255.PubMedGoogle Scholar
  129. 118A.
    Whelton A, Lefkowith JL, West CR, Verburg KM. Cardiorenal effects of celecoxib as compared with the nonsteroidal anti-inflammatory drugs diclofenac and ibuprofen. Kid Internal 2006;70:1495-1502Google Scholar
  130. 119.
    Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.. New England Journal of Medicine 2002;343: 1520-1528.Google Scholar
  131. 120.
    Goldstein JL, Silverstein FE, Agrawal NM et al. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor. American Journal of Gastroenterology 2000;95: 1681-1690.PubMedGoogle Scholar
  132. 121.
    Leese PT, Hubbard RC, Karim A et al. Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial. Journal of Clinical Pharmacology 2000;40: 124-132.PubMedGoogle Scholar
  133. 122.
    127. Gastroenterology 2007.Google Scholar
  134. 123.
    Langman MJ, Jensen DM, Watson DJ et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.. JAMA 1999;282: 1929-1933.PubMedGoogle Scholar
  135. 124.
    O’Neill GP, Ford-Hutchinson AW, O’Neill GP, Ford-Hutchinson AW. Expression of mRNA for cyclooxygenase-1 and cyclooxygenase2 in human tissues. FEBS Letters 1993;330: 156-160.PubMedGoogle Scholar
  136. 125.
    Whelton A, Whelton A. Renal and related cardiovascular effects of conventional and COX-2-specific NSAIDs and non-NSAID analgesics. American Journal of Therapeutics 2000;7: 63-74.PubMedGoogle Scholar
  137. 126.
    Rossat J, Maillard M, Nussberger J et al. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clinical Pharmacology & Therapeutics 1999;66: 76-84.Google Scholar
  138. 127.
    Swan SK, Rudy DW, Lasseter KC et al. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a lowsalt diet. A randomized, controlled trial.. Annals of Internal Medicine 2000;133: 1-9.PubMedGoogle Scholar
  139. 128.
    Whelton A, Fort JG, Puma JA et al. Cyclooxygenase-2--specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. American Journal of Therapeutics 2001;8: 85-95.PubMedGoogle Scholar
  140. 129.
    Perazella MA, Eras J, Perazella MA, Eras J. Are selective COX-2 inhibitors nephrotoxic?. American Journal of Kidney Diseases 2000;35: 937-940.PubMedGoogle Scholar
  141. 130.
    Wolf G, Porth J, Stahl RA, Wolf G, Porth J, Stahl RA. Acute renal failure associated with rofecoxib. Annals of Internal Medicine 2000;133: 394.PubMedGoogle Scholar
  142. 131.
    Ahmad SR, Kortepeter C, Brinker A et al. Renal failure associated with the use of celecoxib and rofecoxib. Drug Safety 2002;25: 537-544.PubMedGoogle Scholar
  143. 132.
    Zhao SZ, Reynolds MW, Lejkowith J et al. A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database. Clinical Therapeutics 2001;23: 14781491.Google Scholar
  144. 133.
    Whelton A, White WB, Bello AE et al. Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis.. American Journal of Cardiology 2002;90: 959-963.PubMedGoogle Scholar
  145. 134.
    Dedier J, Stampfer MJ, Hankinson SE et al. Nonnarcotic analgesic use and the risk of hypertension in US women. Hypertension 2002;40: 604-608.PubMedGoogle Scholar
  146. 135.
    Collins R, Peto R, Godwin J et al. Blood pressure and coronary heart disease. Lancet 1990;336: 370-371.PubMedGoogle Scholar
  147. 136.
    Sowers JR, White WB, Pitt B et al. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Archives of Internal Medicine 2005;165: 161-168.PubMedGoogle Scholar
  148. 137.
    Reitblat T, Zamir D, Estis L et al. The different patterns of blood pressure elevation by rofecoxib and nabumetone. Journal of Human Hypertension 2002;16: 431-434.PubMedGoogle Scholar
  149. 138.
    Dilger K, Herrlinger C, Peters J et al. Effects of celecoxib and diclofenac on blood pressure, renal function, and vasoactive prostanoids in young and elderly subjects. Journal of Clinical Pharmacology 2002;42: 985-994.PubMedGoogle Scholar
  150. 139.
    Heart and Stroke Statistics Upate. American Heart Association 2000.Google Scholar
  151. 140.
    Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.. JAMA 1991;265: 3255-3264.Google Scholar
  152. 141.
    Staessen JA, Fagard R, Thijs L et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997;350: 757-764.PubMedGoogle Scholar
  153. 142.
    Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipidlowering treatment to prevent heart attack trial (ALLHAT ). ALLHAT Collaborative Research Group. JAMA 2000;283: 1967-1975.Google Scholar
  154. 143.
    Staessen JA, Gasowski J, Wang JG et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000;355: 865-872.PubMedGoogle Scholar
  155. 144.
    Houston MC, Houston MC. Nonsteroidal anti-inflammatory drugs and antihypertensives. American Journal of Medicine 1991;90: 42S-47S.PubMedGoogle Scholar
  156. 145.
    Trying times for painkiller choices. Vioxx, Bextra, and Celebrex can increase the risk for heart attack and other cardiovascular problems. So can the old standbys, like ibuprofen and acetaminophen. Harvard Heart Letter 2006;17: 1-3.Google Scholar
  157. 146.
    Bresalier RS, Sandler RS, Quan H et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. New England Journal of Medicine 2005;352: 1092-1102.PubMedGoogle Scholar
  158. 147.
    Rocca B, Davi G. Should patients with osteoarthritis be treated with COX2 inhibitors rather than traditional NSAIDs? Nat Clin Pract Rheumatol. 2007 Apr 3; [Epub ahead of print] No abstract available. Nat Clin Pract Rheumatol 2007 Apr 3; [Epub ahead of print] No abstract available 2007;4.Google Scholar
  159. 148.
    Huaang WF, Hsiao FY, Wen YW, Tsai YW. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults. Clinical Therapeutics 2007;28: 1827-1836.Google Scholar
  160. 149.
    Farkouh ME, Greenberg JD, Jeger RV, Rammanathan K, Verheugt FW. Cardiovascular outcomes in high-risk patients with osteoarthritis treated with Ibuprofen, Naproxen, or Lumiracoxib. Ann Rheum Dis 2007;5: [Epub ahead of print].Google Scholar
  161. 150.
    Solomon SD, Pfeffer MA, McMurray JJ et al. Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation 2006;114: 1028-1035.PubMedGoogle Scholar
  162. 151.
    Bertagnolli MM, Eagle CJ, Zauber AG et al. Celecoxib for the prevention of sporadic colorectal adenomas.. New England Journal of Medicine 2006;355: 873-884.PubMedGoogle Scholar
  163. 152.
    Arber N, Eagle CJ, Spicak J et al. Celecoxib for the prevention of colorectal adenomatous polyps.. New England Journal of Medicine 2006;355: 885-895.PubMedGoogle Scholar
  164. 153.
    ADAPT Research Group. Cardiovascular and Cerebrovascular Events in the Randomized, Controlled Alzheimer’s Disease AntiInflammatory Prevention Trial (ADAPT ). WWW Plosclinicaltrials org 2007;e33: 001-010.Google Scholar
  165. 154.
    Schlienger RG, Jick H, Meier CR, Schlienger RG, Jick H, Meier CR. Use of nonsteroidal anti-inflammatory drugs and the risk of first-time acute myocardial infarction. British Journal of Clinical Pharmacology 2002;54: 327-332.PubMedGoogle Scholar
  166. 155.
    Mamdani M, Rochon P, Juurlink DN et al. Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Archives of Internal Medicine 2003;163: 481-486.PubMedGoogle Scholar
  167. 156.
    Kimmel SE, Berlin JA, Reilly M et al. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Annals of Internal Medicine 2005;142: 157-164.PubMedGoogle Scholar
  168. 157.
    Graham DJ, Campen D, Hui R et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclooxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study.. Lancet 2005;365: 475-481.PubMedGoogle Scholar
  169. 158.
    Hippisley-Cox J, Coupland C, Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis.. BMJ 2005;330: 1366.PubMedGoogle Scholar
  170. 159.
    Fischer LM, Schlienger RG, Matter CM et al. Discontinuation of nonsteroidal anti-inflammatory drug therapy and risk of acute myocardial infarction. Archives of Internal Medicine 2004;164: 2472-2476.PubMedGoogle Scholar
  171. 160.
    Johnsen SP, Larsson H, Tarone RE et al. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study. Archives of Internal Medicine 2005;165: 978-984.PubMedGoogle Scholar
  172. 161.
    Levesque LE, Brophy JM, Zhang B, Levesque LE, Brophy JM, Zhang B. The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Annals of Internal Medicine 2005;142: 481-489.PubMedGoogle Scholar
  173. 162.
    Levesque LE, Brophy JM, Zhang B, Levesque LE, Brophy JM, Zhang B. Time variations in the risk of myocardial infarction among elderly users of COX-2 inhibitors.. CMAJ Canadian Medical Association Journal 2006;174: 1563-1569.Google Scholar
  174. 163.
    Helin-Salmivaara A, Risto VesalainenJuha M.Grönroos, Juha M.Grönroos. NSAID use and the risk of hospitalization for first myocardial infarction in the general population: a nationwide case-control study from Finland. 27, 1657-1663. 2006.Google Scholar
  175. 164.
    Spilding WM, Reeves MJ, Whelton A. Thromboembolic Cardiovascular Risk Among Arthritis Patients Using Cyclooxygenase2-Selective Inhibitor or Nonselective Cyclooxygenase Inhibitor Nonsteroidal Anti-inflammatory Drugs. American Journal of Therapeutics 2007; 3-12.Google Scholar
  176. 165.
    Hawkey CJ, Hawkey GM, Everitt S et al. Increased risk of myocardial infarction as first manifestation of ischaemic heart disease and nonselective nonsteroidal anti-inflammatory drugs. British Journal of Clinical Pharmacology 2006;61: 730-737.PubMedGoogle Scholar
  177. 166.
    McGettigan P, Henry D, McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 2006;296: 1633-1644.PubMedGoogle Scholar
  178. 167.
    Lee TA, Bartle B, Weiss KB, Lee TA, Bartle B, Weiss KB. Impact of NSAIDS on mortality and the effect of preexisting coronary artery disease in US veterans. American Journal of Medicine 2007;120: 98-16.PubMedGoogle Scholar
  179. 168.
    Stillman MJ, Stillman MT. Appropriate use of NSAIDs: considering cardiovascular risk in the elderly. Geriatrics 2007;62: 16-21.PubMedGoogle Scholar
  180. 169.
    Stillman MJ, Stillman MT. Choosing nonselective NSAIDs and selective COX-2 inhibitors in the elderly. A clinical use pathway. Geriatrics 2007;62: 26-34.PubMedGoogle Scholar
  181. 170.
    Heerdink ER, Leufkens HG, Herings RM et al. NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics. Archives of Internal Medicine 1998;158: 1108-1112.PubMedGoogle Scholar
  182. 171.
    Page J, Henry D, Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem.. Archives of Internal Medicine 2000;160: 777-784.PubMedGoogle Scholar
  183. 172.
    Feenstra J, Heerdink ER, Grobbee DE et al. Association of nonsteroidal anti-inflammatory drugs with first occurrence of heart failure and with relapsing heart failure: the Rotterdam Study. Archives of Internal Medicine 2002;162: 265-270.PubMedGoogle Scholar
  184. 173.
    Mamdani M, Juurlink DN, Lee DS et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 2004;363: 1751-1756.PubMedGoogle Scholar
  185. 174.
    Hudson M, Rahme E, Richard H, Piloate L. Risk of congestive heart failure with nonsteroidal antiinflammatory drugs and selective Cyclooxygenase 2 inhibitors: A class effect? Arthritis & Rheumatism 2007;29: 516-523.Google Scholar
  186. 175.
    Johnston HH, Herzog JP, Lauler DP, Johnston HH, Herzog JP, Lauler DP. Effect of prostaglandin E1 on renal hemodynamics, sodium and water excretion. American Journal of Physiology 1967;213: 939-946.PubMedGoogle Scholar
  187. 176.
    Fulgraff G, Brandenbusch G, Fulgraff G, Brandenbusch G. Comparison of the effects of the prostaglandins A1, E2, and F2alpha on kidney function in dogs. Pflugers Archiv - European Journal of Physiology 1974;349: 9-17.PubMedGoogle Scholar
  188. 177.
    Chang LC, Splawinski JA, Oates JA et al. Enhanced renal prostaglandin production in the dog. II. Effects on intrarenal hemodynamics. Circulation Research 1975;36: 204-207.Google Scholar
  189. 178.
    Strandhoy JW, Ott CE, Schneider EG et al. Effects of prostaglandins E1 and E2 on renal sodium reabsorption and Starling forces. American Journal of Physiology 1974;226: 1015-1021.PubMedGoogle Scholar
  190. 179.
    Paller MS, Paller MS. The prostaglandin E1 analog misoprostol reverses acute cyclosporine nephrotoxicity. Transplantation Proceedings 1988;20: 634-637.PubMedGoogle Scholar
  191. 180.
    Weir MR, Klassen DK, Hall PS, Schubert C. Minimization of indomethacin-induced reduction in renal function by misoprostol. Journal of Clinical Pharmacology 1989;31: 729-735.Google Scholar
  192. 181.
    Pincus T, Koch GG, Sokka T, et al. A randomized, double-blind crossover clinical trial of diclofenac versus misoprostol versus acetaminophen in patients with osteoarthritis of the knees or hip. Arthritis Rheum 2001;44:1587-98. PubMedGoogle Scholar
  193. 182.
    Boers M, Dijkmans BA, Breedveld FC et al. No effect of misoprostol on renal function of rheumatoid patients treated with diclofenac. British Journal of Rheumatology 1991;30: 56-59.PubMedGoogle Scholar
  194. 183.
    Whelton A, Scott H, Stout RL. Effects of Misoprostol on Nonsteroidal Anti-Inflammatory Drug-Induced Renal Insufficiency in Patients with Stable Chronic Renal Failure: A Double-Blind, Crossover Study. American Journal of Therapeutics 1995;2: 858-863.Google Scholar
  195. 184.
    Gurkowski L, Macdougal M, Weigmann t. Effects of Misoprostol on Contrast-Induced Renal Dysfunction. American Journal of Therapeutics 1995;2: 837-842.PubMedGoogle Scholar
  196. 185.
    Singh G, Miller JD, Huse DM, et al. Consequences of increased systolic blood pressure in patients with osteoarthritis and rheumatoid arthritis.Google Scholar
  197. 186.
    Kimmel SE, Berlin JA, Reilly M et al. Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Annals of Internal Medicine 2005;142: 157-164.PubMedGoogle Scholar
  198. 187.
    Brophy JM, Levesque LE, Zhang B. The coronary risk of cyclo-oxygenase-2 inhibitors in patients with a previous myocardial infarction. Heart 2007;93: 189-194.PubMedGoogle Scholar
  199. 188.
    Garcia Rodriguez LA, Varas-Lorenzo C, Maguire A et al. Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population. Circulation 2004;109: 3000-3006.PubMedGoogle Scholar
  200. 189.
    Rahme E, Nedjar H. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study. Rheumatology 2007;46: 435-438.PubMedGoogle Scholar
  201. 190.
    Gislason GH, Jacobsen S, Rasmussen JN et al. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation 2006;113: 29062913Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Ali J. Olyaei
    • Andrew Whelton
      • 1
    • Til Sturmer
      • 2
    • George A. Porter
      1. 1.Johns Hopkins UniversityUniversal Clinical Research CenterBaltimoreUSA
      2. 2.German Centre for Research on AgingHeidelbergGermany

      Personalised recommendations